Nyxoah (NYXH) Expected to Announce Earnings on Thursday

Nyxoah (NASDAQ:NYXH) is projected to announce its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Nyxoah to post earnings of ($0.65) per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 12, 2026 at 8:00 AM ET.

Nyxoah Trading Up 5.1%

NYXH stock opened at $3.94 on Thursday. Nyxoah has a 52 week low of $3.74 and a 52 week high of $11.87. The company has a market capitalization of $134.20 million, a PE ratio of -1.58 and a beta of 1.56. The company’s 50-day simple moving average is $4.67 and its 200 day simple moving average is $5.08. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.41 and a current ratio of 1.70.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on NYXH. Stifel Nicolaus decreased their target price on shares of Nyxoah from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Thursday, January 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nyxoah in a research report on Monday, December 29th. Finally, Piper Sandler restated an “overweight” rating and set a $9.00 price objective (down from $12.00) on shares of Nyxoah in a research note on Friday, November 14th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $11.67.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Heights Capital Management Inc. acquired a new stake in shares of Nyxoah in the 4th quarter valued at $3,575,000. Shay Capital LLC bought a new stake in shares of Nyxoah during the 2nd quarter worth $374,000. Citadel Advisors LLC bought a new stake in shares of Nyxoah during the 3rd quarter worth $98,000. Bank of America Corp DE boosted its stake in Nyxoah by 152.7% in the third quarter. Bank of America Corp DE now owns 19,878 shares of the company’s stock valued at $91,000 after buying an additional 12,012 shares in the last quarter. Finally, Deutsche Bank AG grew its position in Nyxoah by 40.0% in the fourth quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after acquiring an additional 10,000 shares during the last quarter.

About Nyxoah

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.